Ladies and gentlemen, good morning and welcome to the Apyx Medical first quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star and zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jeremy Feffer from LifeSci Advisors. Please go ahead. Thank you, and welcome everyone to our first quarter 2025 earnings call. Representing the company on the call are Charlie Goodwin, Chief Executive Officer, and Matt Hill, Chief Financial Officer of Apyx. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including, without limitation, those identified in the risk factors section of our most recent annual report on Form 10-K, our most recent 10-Q filing, and the company's other filings with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events, or otherwise. This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the investor relations portion of our website. I would now like to turn the call over to Mr. Charlie Goodwin, Apyx Medical's President and Chief Executive Officer. Please go ahead. Thank you, Jeremy, and thank you all for joining us today. Per our usual format on these quarterly calls, I will be providing a review of our performance in the first quarter of 2025, and then I will turn the call over to Matt for a review of our first quarter financial results as well as our full year 2025 guidance. We will then open the call for your questions. Let me start with a review of our first quarter performance. We reported total revenue of $9.4 million for the quarter, a decrease of 8% compared to $10.2 million for the same period last year. While sales of our OEM products decreased as expected, sales of our advanced energy products increased 6% to $7.9 million for the first quarter of 2025 compared with last year's period. This reflects a building trend we have seen over the past year with stronger sales of single-use handpieces in the United States. We also continue to see demand for capital equipment stabilize with increases year-over-year for two consecutive quarters in the U.S. We believe this speaks to the benefits offered by Renuvion as the only FDA-cleared device for use after liposuction, as well as its ability to treat loose and lax skin. Digging further into our financial performance for the quarter, I want to point out that our team delivered these solid top-line results somewhat defying the industry. We also implemented significant cost-cutting measures and a restructuring program that right-sized our operations just six months ago. I think these initial results show this program is achieving its intended outcomes of reducing cost, reducing cash burn, and speaks to the dedication of our commercial strategy and vision for Apyx. Matt and I are very appreciative of everyone's effort, and I am truly excited about the direction we are heading. We've laid a strong foundation that is energizing and setting the stage for meaningful growth, innovation, and impact. There are persistent macroeconomic headwinds impacting the global aesthetic space. At the same time, we believe the primary impact on the market is coming from the explosive growth of GLP-1s. We estimate that over 15 million patients are currently using GLP-1 drugs, many of which we believe will seek treatment for loose and lax skin due to the associated rapid weight loss. As I have mentioned previously, we are still in the early innings of this market when it comes to our role in serving these patients' needs as they meet their goal weight. In fact, Dr. Randi Boyette, in her podcast, cited a study of 1,028 GLP-1 patients across 424 clinics examining the top 10 aesthetic treatments after medical weight loss. Number one was skin tightening treatments at 63%, and number two was body contouring fat reduction at 52%. As the only true surgical aesthetics company, we believe we are uniquely positioned to take advantage of this burgeoning tailwind. This brings me to our Renuvion offering. We believe this minimally invasive surgical procedure is the best treatment option to address loose and lax skin, providing a durable and transformational result. It is our belief that Renuvion should be the standard of care for all patients, including those who have lost significant weight as a result of GLP-1 drugs. Our results are supported by long-term data. Just last month, we announced the publication of two peer-reviewed articles on two separate clinical studies that evaluated the use of Renuvion during body contouring procedures, including lipoabdominoplasty following significant weight loss. In these studies, the authors reported that patients in the Renuvion group demonstrated improvements in abdominal skin laxity and excess skin, along with higher satisfaction scores. These papers highlight the use of Renuvion in combination with lift procedures, which are growing more than 20%. Please keep in mind that these newly published data simply reinforce a larger and growing body of evidence supporting the safety and utility of Renuvion in aesthetic body contouring. For further validation, we are excited to announce just a few weeks ago that Renuvion won the 2025 New Beauty Award for Best Minimally Invasive Skin Tightener. As part of this process, New Beauty editors tested thousands of products leading up to the 15th annual awards issue, with a goal of selecting the most innovative beauty products, treatments, and trends. They also collaborate with board-certified doctors and medical experts to determine the most effective, results-driven in-office treatments and post-procedure essentials. We are honored to have our game-changing technology receive this accolade by such a trusted authority in the aesthetic space. Regarding our direct-to-consumer marketing strategy, our program continues to deliver outstanding results, generating significant reach, views, and PR beyond our expectations. As I have mentioned previously, as part of this program, we have successfully leveraged several influencers who each bring a unique voice and engaged audience to our campaign. Most recently, we announced the appointment of Dolores Catania as the Chief of Confidence for the brand's Renew You consumer marketing campaign, which exemplifies the brand's ability to reshape bodies and lives. As a beloved personality of The Real Housewives of New Jersey, Dolores provides a real take on the problem patients face with loose skin and the power of our body contouring technology. She is a powerful advocate for choosing board-certified plastic or cosmetic surgeons for treatments and procedures. This overlaps really well with our messaging that Renuvion is the number one trusted body contouring technology among these doctors, along with clinical data, and we believe she will be a valuable member of the Apyx team. Turning to our development pipeline, we are very excited to have introduced our AYON Body Contouring on our third quarter call following the submission of the 510(k) to the FDA in December. This all-in-one platform seamlessly integrates Renuvion, ultrasound-assisted liposuction, power-assisted liposuction, infiltration, aspiration, electrocoagulation, and fat transfer into a single streamlined device. Considering the major shifts in the market with rapid adoption of GLP-1s, we believe AYON is a game-changer for surgeons that will differentiate us and position Apyx as their surgical partner. Our goal for the next few years is to be able to walk into almost any surgeon's practice and see AYON positioned in the heart of their operating room pending clearance. In late March, we offered an early look at AYON's system to board-certified plastic and cosmetic surgeons during the Aesthetic MEET in Austin, Texas, which is considered the premier event in aesthetics. I am excited to report that the feedback exceeded all expectations as many of the physicians we spoke with confirmed that the AYON would be a welcome addition to many of their practices and provided for all of their surgical needs. Regarding timing, we are preparing for a planned launch of AYON in the back half of 2025 pending clearance. We expect the introduction of the AYON system to the market will help kickstart our equipment sales growth as we have an opportunity to capture new market share and expand our total addressable market in aesthetic surgery. I will now turn the call over to Matt for a review of our first quarter 2025 financial results in more detail along with our financial guidance for 2025. Thanks, Charlie. Before I get started, please note that all references to first quarter financial results will be on a GAAP and year-over-year basis unless otherwise noted. As Charlie mentioned, total revenue for first quarter 2025 decreased 7.9% to $9.4 million compared to $10.2 million in the prior year period. Revenue for the advanced energy segment increased 5.8% to $7.9 million as a result of increased volume of single-use handpieces domestically, domestic and international sales of upgrades of the Apyx One console, and domestic sales of new generators. These increases were partially offset by lower average selling price of generators to domestic customers and a general decrease in international sales. OEM segment sales decreased 44.7% or approximately $1.2 million for first quarter of 2025 when compared to the first quarter of 2024. The decrease in OEM sales was due to decrease in sales volume to existing customers excluding Symmetry Surgical under our 10-year generator manufacturing and supply agreement. Domestic revenue decreased 3.4% year-over-year to $6.7 million, and international revenue decreased 17.7% year-over-year to $2.7 million. As a reminder, there's somewhat of a seasonality to the medical device business where quarterly revenue is normally the lowest in Q1 and Q3 and the highest in Q2 and Q4. Gross profit for the first quarter of 2025 decreased to $5.7 million compared with $5.9 million in the prior year period. Gross profit margin for the first quarter of 2025 was 60.1% compared to 58.1% in the prior year period. The increase in gross profit margins was primarily attributable to the mix between our segments with advanced energy comprising a higher percentage of total sales and geographic mix within our advanced energy segment with domestic sales comprising a higher percentage of total sales. These increases were partially offset by a decrease in the average selling price of generators to domestic customers and product mix within our OEM segment. With respect to tariffs, we are actively monitoring trade policy and tariff announcements, including the recent executive orders issued by the U.S. Federal Administration regarding tariffs on imports from various countries. At this time, the overall impact on our business related to these or any other tariffs that may be imposed remains uncertain and depends on multiple factors. Moving on to operating expenses, which decreased to $8.7 million for first quarter of 2025 compared to $12.6 million in the prior year period. The decrease in operating expenses was driven by a $1.6 million decrease in salaries and related costs, a $1.5 million decrease in selling and general administrative expenses, a $0.6 million decrease in research and development expenses, and a $0.1 million decrease in professional services expenses. Loss from operations decreased $3.6 million or 54% to $3.1 million. Net loss attributable to shareholders was $4.2 million or $0.10 per share for first quarter of 2025 compared with $7.6 million or $0.22 per share in the prior year period. Adjusted EBITDA loss decreased 54% to $2.4 million compared to $5.3 million in the first quarter of 2024. As a reminder, we provided detailed reconciliation from net loss attributable to stockholders to non-GAAP adjusted EBITDA loss in our earnings press release. For the three months ending March 31, 2025, cash used in operating activities decreased to $0.7 million compared to $6.3 million used in the prior year period. We were pleased with the cash and working capital management in first quarter, and we expect to return to more normalized cash burn for the balance of 2025. As of March 31, 2025, the company had cash and cash equivalents of $31 million compared to $31.7 million as of December 31, 2024. We believe, based on our projections, including the uptake of the Apyx One platform, working capital management, and our strict cost controls, we will yield cash into 2027. Turning to a review of our 2025 guidance, which we reaffirmed in our first quarter 2025 financial results press release issued earlier today, for the 12 months ending December 31, 2025, we expect total revenue in the range of $47.6 million-$49 million as compared to $48.1 million for the year ending December 31, 2024. Our revenue guidance assumes advanced energy revenue in the range of $39.6 million-$41 million as compared to $38.6 million for the year ending December 31, 2024. OEM revenue is expected to come in at approximately $8 million as compared to $9.5 million for the year ending December 31, 2024. We see Q2 OEM revenue to be similar to Q1, with the balance of the $8 million to be allocated to the back half of the year. We still anticipate gross margins of approximately 60% for the year and total operating expenses not to exceed $40 million. This completes our prepared remarks. Charlie and I will now open the call for questions. Operator? Thank you, ladies and gentlemen. We will now begin the question and answer session. Should you have a question, please press star followed by one on your touch-tone phone. You will hear a prompt that your hand has been raised. Should you wish to decline from the polling process, please press star followed by two. If you are using speakerphone, please lift the handset before pressing any keys. First question comes from Matt Hewitt with Craig-Hallum Capital Group. Please go ahead. Good morning. Thank you for taking the questions. Obviously, it's nice to hear that you're seeing some stability on the generator side. One of the opportunities with the AYON platform was that for the practices to obtain one of those, they were going to have to kind of get in queue. To do that, you were going to give priority to those that had upgraded to the Apyx One console. How is that progressing? Are you seeing customers enroll for that? What does the pipeline look on that side? Yeah. Thanks, Matt. I appreciate the question. Look, we're not going to comment on the pipeline for AYON yet. We're still waiting for clearance from the FDA, and so we'll have plenty of time to update everybody on AYON and what's going on there. Obviously, the announcement of AYON gives doctors and clinicians a huge impetus to upgrade to the Apyx One because of the excitement around AYON. We're very happy with what we're seeing in the marketplace regarding that. Yeah. I apologize. I could have been a little more clear. I was asking about the Apyx One console, the upgrades to just get in queue for AYON. I was just curious if you were seeing increased demand for the Apyx One ahead of that. Yeah. No, that is actually what I tried to answer. The answer to that is we're happy with what we're seeing for that is the upgrade, is people upgrading to the Apyx One and waiting for AYON. Got it. All right. As far as there was going to be a soft launch later this year, I think last call you had kind of mentioned that you kind of had a list, but have you kind of solidified the list of practices that will be receiving AYON? Are they getting set up? Kind of walk through the process once you do receive approval from the FDA, what that first batch of KOLs, what that'll look like? Yeah. We do. We have that list all solidified. We've got 20 AYON ambassadors throughout the United States that are ready to go once we get clearance. Obviously, we would install the systems, get them and their staffs trained on everything, and then they would obviously start performing cases and give us feedback and all of that. That clock starts when we get clearance and then when we get everything installed and ready to go. We are making great progress with all of that. Now it's just a matter of waiting. Understood. And one last one, and I know you touched on this a little bit in your prepared remarks, but obviously, front of mind for a lot of investors recently has been tariffs. Maybe just remind everyone where you're obtaining your products from and what, if anything, would need to be done to mitigate any potential tariff impact. Thank you. Yeah. No, thanks, Matt. Look, we've got a supply chain where we get parts from all over the world. One of the advantages that we have as a company is we have manufacturing both in the United States and we have manufacturing both in Sofia, Bulgaria. Based on what the environment is and what the best path for us, we can adjust manufacturing between the two facilities. We do have a little bit of flexibility when it comes to that. That's great. Thank you. Mm-hmm. Next question comes from Sam Eiber with BTIG. Please go ahead. Hey, good morning, Charlie and Matt. Thanks for taking the questions here. Maybe I can just follow up on the last question on tariffs. Obviously, I know there's a lot of moving parts here, but I guess as currently contemplated today, any way to size the impact to margins at this point? In Matt's prepared remarks, he talked that we're still expecting gross margins to be around 60% for the entire year. I think that's what we said at the beginning of the year. All of that would impact everything that we know right now based on the current situation. Okay. So it sounds like pretty minimal impact at this point. Maybe I can use my follow-up here on just how you're thinking about investments to support the AYON launch. Obviously, I know you're keeping a close eye on cash burn and operating expenses, but how are you positioning investments to support this launch while also preserving capital here? Yeah. Look, obviously, expense control and cash management is incredibly important to us, but it's not at the expense of the AYON launch. Everything that we've contemplated into our budget and the investments that we're making is there to support AYON and to be able to grow that. Remember, we think that AYON is a huge differentiator for us at Apyx Medical and makes us a true partner for the surgeons. We've got plans for how not only are we going to use capital to build new AYON s, but obviously part of the social strategy to talk about that and everything else. It's always been contemplated in there. We are going to do our best to keep managing expenses and managing our cash burn, but like I said, it won't be at the expense of the launch of AYON. Okay. Very good. Thanks for taking the questions. You bet. There are no further questions. Please continue. Thank you, everyone.